[Form 4] Century Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Brent Pfeiffenberger, President and CEO and Director of Century Therapeutics, Inc. (IPSC), reported a small automatic sale of common stock on 09/08/2025 to satisfy tax withholding related to the vesting of restricted stock units. The Form 4 shows 488 shares were sold at $0.50 per share, and following the reported transaction the reporting person beneficially owns 3,268,909 shares, held directly. The filing states the sales were automatic to cover tax obligations and not at the reporting person’s discretion.

Positive

• Substantial direct ownership retained: Reporting person holds 3,268,909 shares after the transaction, indicating significant alignment with shareholders.
• Transaction was administrative: Sale was automatic to satisfy tax withholding on vested RSUs, as explicitly stated.

Negative

• Minor disposition of shares: 488 shares were sold, which is a reduction in holdings (though immaterial relative to total ownership).

Insights

Corporate Governance Expert

TL;DR: Routine tax-withholding sale; maintains substantial direct ownership, suggesting ongoing alignment with shareholders.

The Form 4 documents an automatic disposition of 488 shares by the CEO/Director to satisfy tax withholding on vested restricted stock units. Such transactions are common, administrative in nature, and the filing explicitly states the sales were automatic and not discretionary. Materiality is low given the small number of shares sold relative to the reported direct beneficial ownership of 3,268,909 shares. From a governance perspective, continued sizable ownership by the CEO/Director generally aligns management incentives with shareholders and there is no indication of unusual timing or pattern in this single filing.

Securities Analyst

TL;DR: Non-material insider sale; transaction stems from RSU tax withholding, not an active disposition signal.

The entry lists a sale code associated with tax withholding following RSU vesting. The price per share reported is $0.50 for 488 shares. Given the remaining direct beneficial ownership reported at 3,268,909 shares, the economic impact of this sale on outstanding insider stake is negligible. There is no derivative activity reported. For investors parsing insider activity, this filing represents routine administrative action rather than a strategic liquidity move.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pfeiffenberger Brent

(Last) (First) (Middle)

C/O CENTURY THERAPEUTICS, INC.

25 N 38TH STREET, 11TH FLOOR

(Street)

PHILADELPHIA PA 19104

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Century Therapeutics, Inc. [ IPSC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/08/2025		S(1)		488	D	$0.5	3,268,909	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

	/s/ Douglas Carr, Attorney-in-Fact	09/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider filed the Form 4 for Century Therapeutics (IPSC)?

The Form 4 was filed for Brent Pfeiffenberger, who is President and CEO and a Director of Century Therapeutics, Inc.

What transaction was reported on the Form 4 filed 09/10/2025 for IPSC?

An automatic sale of 488 shares of common stock on 09/08/2025 at $0.50 per share to cover tax withholding related to vested restricted stock units.

How many Century Therapeutics shares does the reporting person own after the transaction?

The reporting person beneficially owns 3,268,909 shares following the reported transaction.

Was the sale discretionary or automatic?

The filing explicitly states the sales were automatic and not at the discretion of the reporting person, made to cover tax withholding obligations.

Did the Form 4 report any derivative transactions (options, warrants, etc.)?

No. Table II for derivative securities contains no reported transactions in this filing.